[Registry] Clinical Performance Evaluation of the C2i-WGS-MRD Test
Condition: Muscle-Invasive Bladder Cancer
Sponsor: C2i Genomics Inc.
Protocol CA-F01-02: Clinical Performance Evaluation of the C2i-WGS-MRD Test for detecting molecular residual disease (MRD) in bladder cancer patients
Patients with stage II-IIIA muscle-invasive bladder cancer post transurethral resection of bladder tumor (TURBT) with plans for radical cystectomy.
The C2i-Test is currently investigational, but may potentially be applied for evaluation of response to neoadjuvant therapy, predict pathological response, predict recurrence-free survival post-RC, and for patient risk stratification for recurrence post-RC, to inform clinical decision-making.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.